ESHAP therapy effective in a patient with Langerhans cell sarcoma

Int J Hematol. 2008 Jun;87(5):532-537. doi: 10.1007/s12185-008-0075-6. Epub 2008 Apr 17.

Abstract

We describe the rare case of a 53-year-old woman with systemic involvement of Langerhans cell sarcoma (LCS) who had undergone living-related liver transplantation. We chose the CHOP regimen as first-line chemotherapy, and clinical improvement of LCS was obtained. Intensive care was necessary due to the systemic involvement of LCS and severe infectious diseases. After the third cycle of CHOP therapy, however, disease progression was observed, and we administrated a modified ESHAP regimen (etoposide, carboplatin, cytarabine, methylprednisolone) as second-line therapy. A marked response was obtained after four cycles of this combination chemotherapy. Modified ESHAP may be a very effective combination chemotherapy regimen for LCS.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cisplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Langerhans Cell Sarcoma / diagnostic imaging
  • Langerhans Cell Sarcoma / drug therapy*
  • Methylprednisolone / administration & dosage
  • Middle Aged
  • Prednisone / administration & dosage
  • Radiography
  • Remission Induction
  • Vincristine / administration & dosage

Substances

  • Cytarabine
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Prednisone
  • Methylprednisolone

Supplementary concepts

  • CHOP protocol
  • ESAP protocol